Previous work has demonstrated that the transgenic TH-MYCN model of neuroblastoma is receptive to combination therapy, and has a more comparable immune infiltrate to human disease, relative to subcutaneous models (Webb et al., 2020). The gene discussed is MYCN; the disease is neuroblastoma.